Olaparib

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 3720 publications

Targeting NF-κB epigenetic activation and DNA repair deficiency in G34-mutant pediatric diffuse hemispheric glioma with nanoparticles combining PARP inhibition and immune stimulation mediated by CpG dinucleotides.

Targeting NF-κB epigenetic activation and DNA repair deficiency in G34-mutant pediatric diffuse hemispheric glioma with nanoparticles combining PARP inhibition and immune stimulation mediated by CpG dinucleotides.

Journal: bioRxiv : the preprint server for biology

Published: April 10, 2026

Plain language summary of results from the DUO-E study: durvalumab given with or without olaparib in patients with advanced endometrial cancer.

Plain language summary of results from the DUO-E study: durvalumab given with or without olaparib in patients with advanced endometrial cancer.

Journal: Future oncology (London, England)

Published: April 07, 2026

Correction: Cosegregation analysis following an excellent response to olaparib in a pancreatic cancer patient carrier of BRCA2:c.7892 T > C variant enables its reclassification from VUS to pathogenic.

Correction: Cosegregation analysis following an excellent response to olaparib in a pancreatic cancer patient carrier of BRCA2:c.7892 T > C variant enables its reclassification from VUS to pathogenic.

Journal: BJC reports

Published: April 02, 2026

Uncovering BAP1 deubiquitination landscape enhances mechanism elucidation and therapeutic precision for BAP1-deficient pancancers.

Uncovering BAP1 deubiquitination landscape enhances mechanism elucidation and therapeutic precision for BAP1-deficient pancancers.

Journal: Science translational medicine

Published: April 01, 2026

Parkinson's disease linked LRRK2 G2019S drives oxidative nuclear DNA damage and PARP1 hyperactive signaling.

Parkinson's disease linked LRRK2 G2019S drives oxidative nuclear DNA damage and PARP1 hyperactive signaling.

Journal: bioRxiv : the preprint server for biology

Published: March 27, 2026

First Real-World Data of Olaparib Combination Treatment with Abiraterone and Prednisone or Prednisolone in First-Line Metastatic Castration-Resistant Prostate Cancer (mCRPC): Descriptive Analysis of 154 Patients Enrolled in the Early Access Program in France.

First Real-World Data of Olaparib Combination Treatment with Abiraterone and Prednisone or Prednisolone in First-Line Metastatic Castration-Resistant Prostate Cancer (mCRPC): Descriptive Analysis of 154 Patients Enrolled in the Early Access Program in France.

Journal: Drugs - real world outcomes

Published: March 26, 2026

RNF146 enhances olaparib sensitivity in triple-negative breast cancer via XRCC5 downregulation.

RNF146 enhances olaparib sensitivity in triple-negative breast cancer via XRCC5 downregulation.

Journal: Biochemical and biophysical research communications

Published: March 26, 2026

Phase II study of olaparib and durvalumab in patients with metastatic castration-resistant prostate cancer.

Phase II study of olaparib and durvalumab in patients with metastatic castration-resistant prostate cancer.

Journal: Journal for immunotherapy of cancer

Published: March 13, 2026

Real-world evidence for the use of olaparib in pancreatic cancer in Spanish hospitals.

Real-world evidence for the use of olaparib in pancreatic cancer in Spanish hospitals.

Journal: Journal of chemotherapy (Florence, Italy)

Published: March 10, 2026

Quantification of olaparib in human liver microsomes using an ultra-fast UPLC-MS/MS quantitative approach: in vitro and in silico metabolic stability assessment.

Quantification of olaparib in human liver microsomes using an ultra-fast UPLC-MS/MS quantitative approach: in vitro and in silico metabolic stability assessment.

Journal: The Analyst

Published: March 05, 2026

Discovery of Novel and Potent Dual PARP1/ERK Inhibitors as a Promising Strategy for Cancer Therapy.

Discovery of Novel and Potent Dual PARP1/ERK Inhibitors as a Promising Strategy for Cancer Therapy.

Journal: Journal of medicinal chemistry

Published: February 25, 2026

Epacadostat and Olaparib Synergistically Inhibit the Growth of BRCA-Proficient Triple-Negative Breast Cancer by Suppressing the Expression of BRCA1 and RAD51.

Epacadostat and Olaparib Synergistically Inhibit the Growth of BRCA-Proficient Triple-Negative Breast Cancer by Suppressing the Expression of BRCA1 and RAD51.

Journal: Molecules (Basel, Switzerland)

Published: February 24, 2026

Showing 1-12 of 3,720

Last Updated: 04/28/2026